Waldencast’s (WALD) Obagi Medical unveils its latest innovation: Nu-Cil BioStim Scalp Serum. “In my practice, I’m seeing a rising number of patients with hair loss concerns, ranging from those with underlying hormonal contributors, such as PCOS, perimenopause, and postmenopause, to younger men aiming to maintain hair density as they age, to those with thyroid disorders or nutritional deficiencies following significant weight loss,” said Dr. Suzan Obagi, Chief Medical Officer of Obagi. “We’re excited about the launch of Nu-Cil BioStim Scalp Serum because it was designed to address these concerns. It was evaluated in a six-month, double-blind clinical study, with results showing that participants using Nu-Cil BioStim Scalp Serum experienced meaningful improvements as early as two weeks into treatment.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast Gains FDA Approval for Obagi Injectable Gel, Expanding U.S. Market Reach
- Waldencast: FDA approves Obagi saypha MagIQ injectable hyaluronic acid gel
- Waldencast Reports Strategic Growth and New Acquisitions
- Waldencast’s Strategic Positioning and Growth Potential: A Buy Rating Amidst Strategic Review and Financial Restructuring
- Waldencast price target lowered to $3 from $4 at Telsey Advisory